In vitro activity of plazomicin against quinolone-resistant gram-negative bacteria isolated from catheter-associated urinary tract infections

References

• Khan HA, Baig FK, Mehboob R. Nosocomial infections: epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed. 2017;7(5):478–482.
   Web of Science ®Google Scholar
• Kuriyama A, Takada T, Irie H, Sakuraya M, Katayama K, Kawakami D, Iwasaki H, Fowler KE, Tokuda Y, Saint S, et al. Prevalence and appropriateness of urinary catheters in Japanese intensive care units: results from a multicenter point prevalence study. Clin Infect Dis. 2017;64(suppl_2):S127–S130.
   PubMedGoogle Scholar
• Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007;122(2):160–166.
   PubMed Web of Science ®Google Scholar
• Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, Pollock DA, Weiner LM, Sievert DM. National Healthcare Safety Network report, data summary for 2013, device-associated module. Am J Infect Control. 2015;43(3):206–221.
   PubMed Web of Science ®Google Scholar
• Kim ES, Hooper DC. Clinical importance and epidemiology of quinolone resistance. Infect Chemother. 2014;46(4):226–238.
   PubMedGoogle Scholar
• Carson C, Naber KG. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Drugs. 2004;64(12):1359–1373.
   PubMed Web of Science ®Google Scholar
• Thwaites M, Hall D, Stoneburner A, Shinabarger D, Serio AW, Krause KM, Marra A, Pillar C. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2018;92(4):338–345.
   PubMed Web of Science ®Google Scholar
• Weinstein MJ, Marquez JA, Testa RT, Wagman GH, Oden EM, Waitz JA. Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic. J Antibiot (Tokyo)). 1970;23(11):551–554.
   PubMed Web of Science ®Google Scholar
• Serio AW, Keepers T, Krause KM. Plazomicin is active against metallo-β-lactamase-producing Enterobacteriaceae. Open Forum Infect Dis. 2019;6(4):ofz123.
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother. 2014;58(5):2554–2563.
   PubMed Web of Science ®Google Scholar
• Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M, Study Collaborators. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis. 2019;19(1):167.
   PubMedGoogle Scholar
• Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006;6(10):629–640.
   PubMed Web of Science ®Google Scholar
• Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010;13(6):151–171.
   PubMed Web of Science ®Google Scholar
• Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12(1):83–88.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. National Healthcare Safety Network Surveillance (NHSN). Patient safety component manual; 2020. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_current.pdf.
   Google Scholar
• Lee M-TG, Lee S-H, Chang S-S, Lee S-H, Lee M, Fang C-C, Chen S-C, Lee C-C. Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: an analysis of national representative claims database. Medicine (Baltimore)). 2014;93(28):e304.
   PubMed Web of Science ®Google Scholar
• Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician. 2002;65(3):455–464.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. 29th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
   Google Scholar
• CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. CLSI standard M07. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• US Food and Drug Administration. FDA-identified interpretive criteria. Available from: https://www.fda.gov/drugs/development-resources/plazomicin-injection.
   Google Scholar
• Abo-State MAM, Saleh YE, Ghareeb HM. Prevalence and sequence of aminoglycosides modifying enzymes genes among E.coli and Klebsiella species isolated from Egyptian hospitals. J Radiat Res Appl. 2018;11(4):408–415.
   Web of Science ®Google Scholar
• El-Badawy MF, Tawakol WM, El-Far SW, Maghrabi IA, Al-Ghamdi SA, Mansy MS, Ashour MS, Shohayeb MM. Molecular identification of aminoglycoside-modifying enzymes and plasmid-mediated quinolone resistance genes among Klebsiella pneumoniae clinical isolates recovered from Egyptian patients. Int J Microbiol. 2017;2017:8050432.
   PubMed Web of Science ®Google Scholar
• Akers KS, Chaney C, Barsoumian A, Beckius M, Zera W, Yu X, Guymon C, Keen EF, Robinson BJ, Mende K, et al. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J Clin Microbiol. 2010;48(4):1132–1138.
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, Panagea T, Argyropoulou A, Stefanou I, Plakias G, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 2012;24(4):191–194.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of plazomicin tested against enterobacterales isolates collected from U.S. hospitals in 2016–2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides. Antimicrob Agents Chemother. 2020; 64(5):e02418.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother. 2018; 73(12):3346–3354.
   PubMed Web of Science ®Google Scholar
• Lepak A, Lepak A, Grajcevci L, Banach J, Meyer K, Chen D. Comparison of plazomicin disk diffusion vs. gradient diffusion susceptibility testing results against drug-resistant clinical Enterobacteriaceae isolates. Open Forum Infect Dis. 2019;6(Supplement_2):S733–S734.
   Google Scholar
• Machuca J, Ortiz M, Recacha E, Díaz-De-Alba P, Docobo-Perez F, Rodríguez-Martínez J-M, Pascual Á. Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. J Antimicrob Chemother. 2016;71(11):3066–3071.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Davis AP, Serio AW, Krause KM, Mendes RE. In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. Diagn Microbiol Infect Dis. 2019;94(1):73–77.
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Good CE, Hujer AM, Abdelhamed AM, Rhoads DD, Hujer KM, Rudin SD, Domitrovic TN, Connolly LE, Krause KM, et al. Antibacterial Resistance Leadership Group. ARGONAUT II Study of the in vitro activity of plazomicin against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(5):e00012–20.
   PubMedGoogle Scholar
• Fleischmann WA, Greenwood-Quaintance KE, Patel R. In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug resistant aerobic Gram-negative bacilli. Antimicrob Agents Chemother. 2020;64(2):e01711-19.
   PubMed Web of Science ®Google Scholar
• Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ. Teaching an old class new tricks: a novel semi-synthetic aminoglycoside, plazomicin. Infect Dis Ther. 2019;8(2):155–170.
   PubMed Web of Science ®Google Scholar
• Landman D, Kelly P, Bäcker M, Babu E, Shah N, Bratu S, Quale J. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother. 2011; 66(2):332–334.
   PubMed Web of Science ®Google Scholar